News | Dermatology

News

Pharmacists should be able to refer patients directly to secondary care for skin conditions, says APPG chair

Exclusive: Taiwo Owatemi, chair of the All-Party Pharmacy Group, has said pharmacists could "easily" help with dermatology referrals.…

Published: 20 February 2023

Opinion

Closing the MPharm awarding gap

It is vital that we work to reduce the awarding gap between white students and black, Asian and minority ethnic students — the race equity programme at the University of Sussex is an example of what can be achieved through collaboration between students and staff.…

Published: 10 October 2022

Feature

‘We are trained to work safely and within certain parameters’

Dianne Sanderson, senior clinical pharmacist and dermatology pharmacist, Vernova Healthcare, Cheshire…

Published: 6 October 2022

News

More than half of pharmacists have been asked about medicines that patients had seen on social media, finds survey

Exclusive: In a survey of nearly 1,600 pharmacists, 910 said a patient had asked them about medicines or products they had seen on social media.…

Published: 21 September 2022

News

Biologic shown to reduce eczema symptoms in young children by three quarters

More than half of the children in the study had at least a 75% reduction in signs of eczema, as well as reductions in itch and improved sleeping patterns.…

Published: 16 September 2022

News

Topical corticosteroids to come with warning about withdrawal effects following MHRA review

The Medicines and Healthcare products Regulatory Agency says withdrawal symptoms from topical corticosteroids include skin redness, burning and/or itchiness, which may be followed by skin peeling.…

Published: 17 September 2021

Feature

Managing childhood eczema: a visual guide

Research has revealed concerns about using topical corticosteroids in children with eczema, both among parents and pharmacists, leading to suboptimal treatment that perpetuates the condition.…

Published: 19 August 2021

Supported content

News

Addition of baricitinib to mainstay of treatment improves signs and symptoms of atopic dermatitis, study finds

Adding the oral selective Janus kinase 1 and 2 inhibitor, baricitinib, to topical corticosteroid treatment significantly improves the signs and symptoms of moderate-to-severe atopic dermatitis, a phase III study in JAMA Dermatology has suggested.…

Published: 15 October 2020

News

Oral therapy abrocitinib is effective in moderate-to-severe atopic dermatitis

Abrocitinib, an oral Janus kinase 1 selective inhibitor, is effective and well-tolerated in patients with moderate-to-severe atopic dermatitis, a study in JAMA Dermatology has suggested.…

Published: 26 August 2020

News

‘No evidence’ that daily emollient use prevents eczema in high-risk newborns

Applying daily emollient during the first year of life does not seem to prevent eczema in high-risk children and could increase the risk of skin infections, a study published in The Lancet has suggested.…

Published: 9 March 2020